The Texas-based 503A compounding facility was warned for continuing to manufacture large amounts of weight loss drugs that are “essentially copies” of brand-name products, which is no longer permitted now that shortages have resolved.
Three senior employees of the pill press company have been arrested as the U.S. House unanimously passes the Stop Pills That Kill Act, which attempts to disrupt the pill press trade.
“Don’t overlook the most consequential finding in this letter. The FDA flagged prescriber determinations that appeared verbatim across hundreds of patient records – like copy-pasted language, pre-loaded for selection, never actually written for an individual patient. The FDA made clear that approach does not meet the bar for prescribing a compounded drug, which must be tailored to the needs of an individual patient.
…
“The FDA must follow this letter with action – seizures and injunctions where warranted – and Congress should work quickly to close the policy gaps that have allowed this shadow drug supply to persist. Patients deserve medicines they can trust.”
Centric Compounding received nine reports of adverse events related to the injections.
A UCLA Health review of 565 studies on six popular unapproved peptides concluded that marketing claims about peptides are far ahead of the science.
The study concludes that the “critical gaps” in oversight pose significant patient safety risks, especially in sterile drug production.
Between February and July, the media covered pill press seizures in 13 states and customs forfeiture records reported seizures of 16 pill presses, six capsule-filling machines, and over 300 pill press parts, dies, and molds. Learn more about the last six months in pill press news.
May and June 2026 saw thousands of shipments of drugs imported into the US, including weight loss drugs and antibiotics. We studied these shipments to learn more about their manufacturers and contents.
Black market users lost an average of 4.7%, 5.3%, and 7.2% of their weight after taking “reta” for three months, six months, and one year, respectively. Those in clinical trials lost an average of 5.7%, 11.9%, and 15.5% over the same time intervals.
The unapproved retatrutide market holds immense safety risks, and patient safety and consumer groups are urging regulators, law enforcement, and the healthcare community to act decisively to protect Americans.